* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Psychopharmacology and Other Biologic Treatments
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Plateau principle wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Serotonin syndrome wikipedia , lookup
Toxicodynamics wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Atypical antipsychotic wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacognosy wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Drug design wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Antipsychotic wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Drug interaction wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Psychopharmacology and Other Biologic Treatments Chapter 8 Psychopharmacology • Subspecialty of pharmacology that includes medications affecting the brain and behavior used to treat mental disorders including – – – – – antipsychotics mood stabilizers antidepressants antianxiety medications stimulants • Provides a basis for understanding specific biologic treatments of psychiatric disorders Pharamacodynamics: Where Drugs Act • Four sites of action – Receptors (those sites to which a neurotransmitter can specifically adhere to produce a change in the cell membranes) – Ion channels – Enzymes – Carrier Proteins • Biologic action depends on how its structure interacts with a receptor. Receptors • Types of Action – Agonist: same biologic actin – Antagonist: opposite effect • Interactions with a receptor – Selectivity: specific for a receptor – Affinity: degree of attraction – Intrinsic activity: ability to produce a biologic response once it is attached to receptor Ion Channels • Drugs can block or open the ion channels • Example: benzodiazepine drugs facilitate GABA in opening the chloride ion channel Enzymes • Enzymes catalyze specific biochemical reactions within cells and are targets for some drugs. • Monoamine oxidase is an enzyme that breaks down most bioamine neurotransmitters (NE, DA, 5-HT). • Enzymes may be inhibited to produce greater neurotransmitter effect. Carrier Proteins • Transport neurotransmitters across cell membranes • Medications may block or inhibit this transport. • Example: antidepressants Efficacy and Potency • Efficacy - Ability of a drug to produce a response as a result of the receptor or receptors being occupied. • Potency - Dose required to produce the desired biologic response. • Loss of effect – desensitization (rapid decrease in drug effect) – tolerance (gradual decrease in the effect of a drug at a given dose) – can lead to being treatment refractory Target Symptoms and Side Effects • Target symptoms: – Specific symptoms for each class of medication – No drug attacks such a target symptom • Side effects - Responses not related to target symptoms (Table 8.1, 8.1). • Adverse effects: Unwanted effects with serious physiologic consequences. Drug Toxicity • Toxicity: Point at which concentrations of the drug in the blood stream become harmful or poisonous to the body. • Therapeutic index: Ratio of the maximum nontoxic dose to the minimum effective dose. • High therapeutic index: Wide range between dose at which the rug begins to take effect and dose that would be considered toxic. • Low therapeutic index - low range Absorption • From site of administration into the plasma • Oral - (tablet and liquid) (Table 8-3) – Most Convenient – Most variable (food and antacids) • First pass effect • Decreased Gastric Motility (age, disease, medication) • IM - Short-and long acting • IV - Rarely used Pharmacokinetics: How the Body Acts on the Drug • Absorption • Distribution • Metabolism • Elimination Bioavailability • Amount of drug that reaches systemic circulation unchanged • Often used to compare one drug to another, usually the higher the bioavailability, the better. Distribution • Amount of drug found in various tissues, especially the intended ones. • Psychiatric drugs must pass through blood-brain barrier (most fat-soluble) • Factors effecting distribution – – – – Size of organ ( larger requires more) Blood flow ( more, greater concentration) Solubility (greater, more concentration) Plasma Protein (if bound, slower distribution, stays in body longer – Anatomic Barriers (tissues surrounding) Crossing the Blood Brain Barrier • Passive diffusion – Drug must dissolve in the structure of the cell – Lipid solubility is necessary for drugs passing through blood brain barrier (then, can also pass through placenta) • Binding to other molecules – Plasma protein binding – The more protein binding, the less drug activity. – Can bind to other cells, especially fat cells. Then are released when blood level decreases. Metabolism • Process by which the drug is altered and broken down into smaller substances (metabolites) that are usually inactive. • Lipid-soluble drugs become more water soluble, so they may be more readily excreted. • Most metablism is carried out in the liver. Cytochrome P450 • Many process carried out by enzyme class Cytochrome P-450 – high affinity for fat-soluble drugs – involved in metabolism of most psychiatric medications – Example: SSRIs inhibitors of the subfamily P4502D6 Elimination • Clearance: Total amount of blood, serum, or plasma from which a drug is completely removed per unit time. • Half-life: Time required for plasma concentrations of the drug to be reduced by 50%. • Only a few drugs eliminated by kidneys (lithium) • Most excreted in the liver – excreted in the bile and delivered to the intestine – may be reabsorbed in intestine and “re-circulate” (up to 20%) Dosing and Steady State • Dosing: Administration of medication over time, so that therapeutic levels can be achieved. • Steady-state: – drug accumulates and plateaus at a particular level – rate of accumulation determined by half life – reach steady state in about five times the elimination half-life Pharmacokinetics: Cultural Considerations • 9% of whites - genetically defective P-4502D6 • Asian descent – Metabolize ethanol to produce higher concentrations of acetaldehyde (flushing, palpitations) – Require 1/2 to 1/3 dose antipsychotics and more severe side effects • Cardiovascular effects of propranolol – Asian descent - more sensitive – African descent - less sensitive Phases of Drug Treatment • • • • Initiation Stabilization Maintenance Discontinuation Psychiatric Medications • Antipsychotic Medications • Movement Disorders Medication • Mood Stabilizers – Antimania – Antidepressants • Antianxiety and Sedative-Hypnotic • Stimulants Antipsychotic Medications • Target symptoms: psychosis • Types – Conventional – Atypical • Absorption: variable – clinical effects seen 30-60 min – IM less variable (avoid 1st pass) – when immobile, less absorption • Metabolism: liver Antipsychotic Medications • Target symptoms: psychosis • Types – Conventional – Atypical • Absorption: variable – clinical effects seen 30-60 min – IM less variable (avoid 1st pass) – when immobile, less absorption • Metabolism: liver • Excretion: slow – accumulates in fatty tissues – 1/2 life of 24 hours or more Antipsychotic Medications (cont..) • Preparations – Oral – IM – Depot - haloperidol and fluphenazine • Side Effects – Cardiovascular - orthostatic Hypertension – Weight-gain: blocking histamine receptor – Endocrine and sexual: block dopamine, interfere with prolactin – Blood Dyscrasias - agranulocytosis Antipsychotic Medications • Conventional – – – – Phenothiazines (Thorazine, Prolixin) Thioxanthenes (Navane) Dibenzoxazepines (Loxitane) Haloperidol (Haldol) • Atypical or Novel – – – – – Clozapine (Clozaril) Risperidone (Risperdal) Olanzapine (Zyprexa) Quetiapine (Seroquel) Ziprasidone (Geodon) Antipsychotic Side Effects • • • • • • Cardiovasular Anticholinergic Weight Gain Endocrine and Side Effects Blood Disorders Miscellaneous Medication-Related Movement Disorders: Acute Syndromes • Can occur in 90% of all patients • Dystonia: involuntary muscle spasms, abnormal postures, oculogyric crisis, torticollis • Parkinsonism: rigidity, akinesia (slow movement), and tremor, masklike face, loss of spontaneous movements • Akathisia: Inability to sit still, restlessness Movement Disorders: Acute (cont.) • Etiology (acute): – Related to dopamine in nigrostrial pathway that increases cholinergic activity • Treatment – Anticholinergic Medication for dystonia, parkinsonism (Artane and Cogentin) – Akathisia does not usually respond to anticholinergic medication. Beta blockers have best success. Movement Disorders: Chronic • Tardive Dyskinesia – Irregular, repetitive involuntary movements of mouth, face, and tongue, including chewing, tongue protrusion, lip smacking, puckering of the lips, and rapid eye blinking. Abnormal finger movements are common. • Symptoms – Begin after 6 months, but also as antipsychotics are withdrawn – Irreversible - controversy Movement Disorders: Chronic • Etiology – believed that chronic dopamine suppression in the EPS causes an overactivation of the system – increases in antipsychotic meds, suppresses • Treatment – prevention by using lowest possible dosage, minimize use of PRN, closely monitor individuals in high-risk groups – monitoring tools Mood Stabilizers: Antimania Lithium Carbonate • Action: uncertain, crosses cell membranes, altering sodium transport, not protein bound • Side Effects: thirst, metallic taste, increased frequency or urination, fine head and hand tremor, drowsiness, and mild diarrhea • Blood levels monitored (lithium toxicity - severe diarrhea, vomiting, drowsiness, muscular weakness, and lack of coordination, withhold) Lithium Carbonate • Monitor creatinine concentrations, thyroid hormones, and CBC every 6 months. • Kidney damage may be a risk. • Thyroid function may be altered usually after 6-18 months. Observe for dry skin, constipation, bradycardia, hair loss, cold intolerance. • Avoid during pregnancy. Mood Stabilizers: Antimania Anticonvulsants • Valporate and derivatives (divalproex sodium - Depakote) • Carbamazapine (Tegretol) • Gabapentin (Neurontin) (least side effects) • Lamotrigine (Lamictal) • Topiramate (Topamax) Anticonvulsant Mood Stabilizers • Only carbamazepine is approved for mania. • Used when patients have not responded to lithium • Pharmacokinetics – Highly protein bound, metabolized by P450 system (potential drug-drug interaction) Carbamazepine Side Effects • Dizziness, drowsiness, tremor, visual disturbances, nausea, and vomiting • Minimized by treating in low doses • Give with food • Weight gain • Alopecia (hair loss) Antidepressants Table 8.11,12 Tricyclic: Tertiary Amines • • • • • Amitriptyline (Elavil) Clomipramine (Anafranil) Doxepine (Sinequan) Imipramine (Tofranil) Trimipramine (Surmontil) Antidepressants Secondary Amines • • • • Amoxapine (Asendin) Desipramine (Norpramin) Nortriptyline (Aventyl, Pamelor) Protrypyline (Vivactil) Side Effects -- TCAs • Most common uncomfortable side effects – sedation – orthostatic hypotension – anticholinergic • Others – – – – – • tremors, restlessness, insomnia, confusion pedal edema, headache, and seizures Blood dyscrasias Sexual dysfunction Adverse – cardiotoxicity Antidepressants • Most antidepressants block the re-uptake of a neurotransmitter of one or more of the bioamines: serotonin, norepinephrine, dopamine. • SSRIs - selective to the serotonin Serotonin Selective Reuptake Inhibitors SSRI – – – – Fluoxetine (Prozac) Sertraline (Zoloft) Paroxetine (Paxil) Fluvoxamine (Luvox) Side Effects -- SSRIs • • • • • • • Headache Anxiety Transient nausea Vomiting Diarrhea Weight gain Sexual dysfunction SSRIs • Usually given in morning, unless sedation occurs • Higher doses, especially fluoxetine, can produce sedation • Venlafaxine (Effexor), only mildly sedating. • Paroxetine associated with weight gain Antidepressants Others • • • • • • Mirtazapine (Remeron) Maprotiline (Ludiomil) Trazodone (Desyrel) Nefazodone (Serzone) Bupropion (Wellbutrin) Venlafaxine (Effexor) Antidepressants Monoamine Oxidase Inhibitors (MAOIs) • Action: Inhibit enzyme responsible for the metabolism of serotonin, dopamine, norepinephrine, and tyramine. • Increases levels of norepinephrine and serontonin in the CNS • Interacts with food -- low tyramine diet (Table 18.3) Antianxiety and SedativeHypnotic Medication • Used for anxiety, not long-term • Benzodiazepines (Table 8.14) – diazepam (Valium) – lorazepam (Ativan) – alprazolam (Xanax) • Nonbenzodiazepines – busipirone (BuSpar) – zolpidem (Ambien) • Side effects – Sedation and CNS depression – Tolerance and dependence (Benzos) – Avoid Benzo in elderly Stimulants • Amphetamines • Used in narcolepsy, ADHD, and obesity Electroconvulsive Therapy • Initiate generalized seizures by an electrical current • Short-acting anesthetic and muscle relaxant given • Repeat procedure 2-3 times per week • Produces rapid relief of depressive symptoms • Side Effects-hypo or hypertension, bradycardia or tachycardia, and minor arrhythmias immediately after Other Biological Treatment • Light Therapy (Phototherapy) – Reset circadian rhythms – Used for SAD • Nutritional Therapies